Drug intelligence / Profile preview

SynVC

Development stage: Preclinical
Lead developer: Accellvecs
Modality: Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Injection

Overview

SynVC is an autologous cell therapy developed by Accellvecs for the treatment of solid tumors. The therapy involves encapsulating a patient's own tumor cells with alpha-galactosylceramide (KRN7000), a potent natural killer T (NKT) cell-activating compound. Following encapsulation, cell death is induced in the tumor cells to create a therapeutic vector. When administered back to the patient, SynVC releases KRN7000 and tumor-specific neoantigens, which simultaneously activate NKT cells and dendritic cells (DCs). The activated DCs then present these neoantigens to the immune system, triggering the production of tumor-specific killer T cells and antibodies from B cells. This approach aims to harness both innate and adaptive immune responses to treat various types of cancer.

Other names: Autologous Tumor Cell Vector

Targets

iNKT TCR (Invariant natural killer T-cell receptor)

Beyond the preview

Go deeper on SynVC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynVC.

Explore the full profile